Guidelinemoderate evidence
Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·September 22, 2026·PMID 42768976
Why it mattersClinicians managing menopausal women with cardiovascular risk or established ischemic heart disease need clear, evidence-based guidance on the safety and selection of MHT. This position paper offers practical recommendations for risk stratification and regimen choice, helping to balance symptom relief with cardiovascular safety.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled